Matt Mitchko

Dova PharmaceuticalsSenior Territory Business Manager, Pittsburgh Region

C: 412-897-8527 Email mmitchko@dova.com

Chat  with Matt

 

 

 

 

 

                           

 

https://dova.com/

 

HCP Website

http://doptelethcp.com/

http://dova1source.com/

Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve the health and well-being of patients in this community. Dova is a wholly-owned subsidiary of Swedish Orphan BiovitrumAB (publ) (Sobi).

Product Summary

DOPTELET® (avatrombopag) is a thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Doptelet ITP Quick Hit_.pdf

doptelet-prescribing-information.pdf

Patient Education Brochure.pdf

   

                            

                           

 

Back to the Virtual Exhibit Hall